Nuclear for Healthcare

Innovating solutions in medical isotopes, radiation-based diagnostics and a new generation of targeted therapies at the heart of the fight against cancer. 

Targeted therapies against cancer

<p>At the heart of the fight against cancer, Orano aims to develop a new generation of targeted therapies using the unique properties of lead-212, a rare alpha-emitting radioisotope with powerful cytotoxic effects.</p>

13 solutions for Nuclear for Healthcare

Our expertise

Drawing on its proven expertise, Orano brings nuclear excellence to healthcare through the development and supply of strategic medical isotopes and innovative radiological solutions. The group provides isotopes such as xenon, molybdenum, zinc, tellurium and ytterbium, which are essential for diagnostics, imaging, and therapeutic applications, alongside sealed radioactive sources used in calibration, and medical device quality control.

More specifically, the group is a pioneer in targeted alpha therapy with lead-212, an innovative isotope that selectively attacks cancer cells while limiting toxicity to healthy tissue. By combining expertise in isotope production, radiopharmaceutical innovation, and nuclear medicine, Orano helps strengthen diagnostics, secure isotope supply, and accelerate next-generation cancer treatments worldwide.